PubRank

Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO (PCD=OOALZ)

Clinical Trial ID NCT02835716

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02835716

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010 3.98
2 Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med 2012 3.49
3 Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord 2008 2.30
4 Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial. Ann Intern Med 2016 1.47
5 Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am J Clin Nutr 2010 1.25
6 Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer's disease. Neuroimage 2011 1.15
7 Prediction of cognitive decline in healthy older adults using fMRI. J Alzheimers Dis 2010 1.12
8 Individual prediction of cognitive decline in mild cognitive impairment using support vector machine-based analysis of diffusion tensor imaging data. J Alzheimers Dis 2010 1.10
9 Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol 2013 1.03
10 Phosphodiesterases as therapeutic targets for Alzheimer's disease. ACS Chem Neurosci 2012 1.03
11 Assessment of Alzheimer's disease risk with functional magnetic resonance imaging: an arterial spin labeling study. J Alzheimers Dis 2012 0.96
12 Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview. Curr Pharm Des 2015 0.94
13 Arterial spin labeling may contribute to the prediction of cognitive deterioration in healthy elderly individuals. Radiology 2014 0.92
14 Early indications of future cognitive decline: stable versus declining controls. PLoS One 2013 0.89
15 Neuroinflammatory cytokine signaling and Alzheimer's disease. N Engl J Med 2013 0.88
16 A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease. Alzheimers Dement 2014 0.87
17 Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. BMC Med 2012 0.85
18 Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease. Neurotherapeutics 2015 0.84
19 Preventing cognitive decline in preclinical Alzheimer's disease. Curr Opin Pharmacol 2013 0.82
20 Emerging therapeutics for Alzheimer's disease. Annu Rev Pharmacol Toxicol 2014 0.81
21 A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. Prog Neurobiol 2013 0.79
22 The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review. Aging Clin Exp Res 2012 0.79
23 The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. J Prev Alzheimers Dis 2014 0.78
24 The Biomarkers for Identifying Preclinical Alzheimer's Disease via Structural and Functional Magnetic Resonance Imaging. Front Aging Neurosci 2016 0.78
25 Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'. J Intern Med 2016 0.77
26 Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics. Expert Rev Neurother 2016 0.76
Next 100